MedTrace Logo

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC

NCT01063478 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-01-17

No results posted yet for this study

Summary

The purpose of this study is to understand the effects (good and/or bad) of the addition of RAD001 to standard radiation and chemotherapy (cisplatin and pemetrexed) for patients with non-small cell lung cancer.

Conditions

Interventions

DRUG

RAD001 (in addition to standard radiation and chemotherapy)

Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001

Sponsors & Collaborators

Principal Investigators

  • Everett E Vokes, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-06-30
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01063478 on ClinicalTrials.gov